MP56-02 SAFETY AND EFFICACY OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM IN THE TREATMENT OF ACTIVE PHASE PEYRONIE'S DISEASE

Abstract

You have accessJournal of UrologySexual Function/Dysfunction: Peyronie’s Disease II1 Apr 2017MP56-02 SAFETY AND EFFICACY OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM IN THE TREATMENT OF ACTIVE PHASE PEYRONIE'S DISEASE James Anaissie, Kenneth DeLay, Nora Haney, Faysal Yafi, and Wayne Hellstrom James AnaissieJames Anaissie More articles by this author , Kenneth DeLayKenneth DeLay More articles by this author , Nora HaneyNora Haney More articles by this author , Faysal YafiFaysal Yafi More articles by this author , and Wayne HellstromWayne Hellstrom More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.1755AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To examine the efficacy and safety of collagenase Clostridium histolyticum (CCH) in the treatment of acute phase Peyronie's Disease (PD). METHODS We conducted a retrospective review of the records for all patients treated with CCH for PD between 04/2014 and 03/2016. Patients qualified as being in the acute phase of PD if they reported penile pain and duration of PD < 12 months at presentation. The primary outcomes of interest were final change in curvature after CCH treatment regardless of number of CCH cycles received, and frequency of treatment-related adverse events (TRAE). Paired t-Test and Chi-squared tests were performed to determine statistical significance (P<0.05). RESULTS A total of 77 patients were included in the study, of which 21 (27%) qualified as acute phase PD and the remaining 56 (73%) as stable phase. Median duration of PD was 8 months for acute phase patients, and 21 months for stable phase (p=0.033). There was no significant difference in final change in curvature between the acute and stable phase of PD (16.2° vs. 14.9°, p=0.702). There was a significant difference in change in curvature reported after the first cycle of treatment between the acute and stable phase (21.7° vs. 12.5°, p=0.037). There was no statistically significant difference in frequency of TRAEs between the acute phase (3, 14%) and the stable phase (4, 7%) (p=0.332). CONCLUSIONS Although CCH is currently contraindicated during the acute phase of PD, preliminary results suggest that CCH use during this setting may be both effective and safe. There was no statistically significant difference in final change in curvature or TRAEs after CCH therapy between the acute and stable phase of PD. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e755 Advertisement Copyright & Permissions© 2017MetricsAuthor Information James Anaissie More articles by this author Kenneth DeLay More articles by this author Nora Haney More articles by this author Faysal Yafi More articles by this author Wayne Hellstrom More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...